Key Takeaways ABBV shares fell 3.2% in a month after it denied reports of talks to acquire Revolution Medicines.ABBV is offsetting Humira LOE as Skyrizi & Rinvoq delivered $18.5B in sales in the first nine months of 2025.ABBV faces Aesthetics weakness and Humira erosion, but oncology and neuroscience growth lift revenues.AbbVie (ABBV) stock has declined 3.2% in a month. Shares of this large drugmaker dipped recently after it denied takeover talks with Redwood City, CA-based cancer biotech, Revolution Medici ...

Core Insights - AbbVie Inc. is highlighted as a strong investment opportunity for the next decade, with recent price target increases from Morgan Stanley and HSBC indicating positive market sentiment [1][2]. Financial Performance - In Q3 2025, AbbVie reported total net revenues of approximately $15.8 billion, marking a 9.10% year-over-year increase, driven by growth in immunology and neuroscience treatments [3]. - The company earned $1.86 per share, surpassing estimates by $0.08 [3]. - The immunology segment generated $7.9 billion in revenue, reflecting an 11.2% increase [3]. Product Performance - Skyrizi sales surged by 46% to $4.7 billion, while Rinvoq sales increased by 34.1% to around $2.2 billion, contributing significantly to revenue growth [4]. - The decline of Humira was noted, with sales dropping 55.7% to $993 million due to the impact of biosimilars [4]. - The oncology sector remained stable, generating $1.7 billion in revenue, with newer drugs like Venclexta offsetting price negotiation impacts on Imbruvica [4]. Market Position - Analysts have downplayed competitive threats from Johnson & Johnson's Tremfya, asserting it is unlikely to significantly impact Skyrizi's market dominance [2].

Key Takeaways AbbVie is rebounding post-Humira, with Skyrizi and Rinvoq sales up 53% Y/Y and expected to top $25B in 2025.AZN's newer drugs are driving growth as it targets $80B in revenues by 2030.Both face pressures: ABBV from aesthetics softness, AZN from China policy impacts and biosimilar erosion.AbbVie (ABBV) and AstraZeneca (AZN) are both global healthcare companies with diversified drug portfolios. Both companies have strong leadership positions in immunology and oncology areas.While AbbVie also has ...

Investors with a lot of money to spend have taken a bullish stance on AbbVie (NYSE:ABBV).And retail traders should know.We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABBV, it often means somebody knows something is about to happen.So how do we know what these investors just did? Today, Benzinga's options scanner spotted 16 ...

Core Insights - AbbVie's stock has recently slipped below its 50-day simple moving average (SMA), indicating recent selling pressure, despite a recovery after a post-earnings dip [1][2][8] - The company has successfully launched new drugs, Skyrizi and Rinvoq, which are expected to drive revenue growth in the coming years, offsetting declines from Humira and the Aesthetics unit [5][7][29] Financial Performance - AbbVie reported combined sales of Skyrizi and Rinvoq at $18.5 billion for the first nine months of 2025, with expectations to exceed $25 billion in 2025 and $31 billion by 2027 [6][7] - The oncology segment generated revenues of $5.0 billion in the first nine months of 2025, a 2.7% year-over-year increase, driven by new drug sales [10] - Neuroscience drug sales increased by 20.3% to nearly $7.8 billion in the same period, supported by products like Botox Therapeutic and Vraylar [11] Market Challenges - Humira's sales have declined over 50% in the first nine months of 2025 due to biosimilar erosion, significantly impacting overall revenue [15] - The Aesthetics segment has seen a 7.4% decline in global sales, with Juvederm and Botox Cosmetics sales falling by 16.7% and 7.4%, respectively [16][17] Strategic Initiatives - AbbVie has been actively pursuing acquisitions to enhance its early-stage pipeline, completing over 30 M&A transactions since early 2024 [14] - The company recently settled patent litigation for Rinvoq, extending its patent exclusivity to 2037, which is expected to bolster its revenue stream [9] Future Outlook - AbbVie anticipates returning to mid-single-digit revenue growth in 2025, driven by strong performances from Skyrizi and Rinvoq, with a high single-digit CAGR projected through 2029 [29] - The company has increased its quarterly cash dividend by 5.5%, reflecting confidence in future growth despite recent estimate declines [30]

Core Insights - AbbVie is significantly expanding its oncology presence, moving from a two-drug franchise to include solid tumors, with new drugs like Epkinly, Elahere, and Emrelis contributing to over 11% of total revenues in the first nine months of 2025, reflecting a 3% year-over-year growth [1][9] Expansion Strategies - The expansion is driven by both organic and inorganic strategies, with Emrelis being AbbVie's first internally developed solid tumor drug, while Epkinly and Elahere were acquired through collaborations [2] - Sales from newer drugs and rising Venclexta sales have offset the decline in Imbruvica sales due to competition from novel therapies [2] Pipeline Development - AbbVie has a diverse pipeline of new therapies for blood cancers and solid tumors, including antibody-drug conjugates (ADCs), which are seen as a disruptive innovation in cancer treatment [3] - A regulatory filing for the ADC therapy pivekimab sunirine is under FDA review for treating a rare blood cancer, which could add a third ADC to AbbVie's portfolio [4] - The company is also developing Temab-A for metastatic colorectal cancer and other cancers in various stages of clinical trials [4][5] Competitive Landscape - Major competitors in the oncology space include AstraZeneca, Merck, and Pfizer, with AstraZeneca's oncology sales accounting for 43% of total revenues and growing 16% year-over-year [6] - Merck's Keytruda accounted for about 48% of its total revenues, while Pfizer's oncology revenues grew 7%, making up over 27% of its total revenues [7] Financial Performance - AbbVie shares have outperformed the industry year to date, trading at a slight discount with a P/E ratio of 15.87 compared to the industry average of 16.31 [8][11] - EPS estimates for 2025 and 2026 have declined in the past 60 days, indicating potential challenges ahead [13]

Core Insights - Financial giants are showing a bearish sentiment towards AbbVie, with 33% of traders indicating bearish tendencies compared to 11% bullish [1] - Significant investors are targeting a price range for AbbVie between $100.0 and $260.0 over the past three months [2] - AbbVie has a diverse portfolio in immunology and oncology, bolstered by recent acquisitions [8] Trading Activity - Recent options activity for AbbVie includes 9 unusual trades, with 4 puts valued at $326,123 and 5 calls valued at $230,186 [1] - The largest observed options trades include neutral sentiment for puts and bullish sentiment for certain calls, with notable strike prices [7] Analyst Ratings - Analysts have varying target prices for AbbVie, with an average target of $251.0 and individual targets ranging from $220 to $289 [10][11] - JP Morgan maintains an Overweight rating with a target price of $260, while UBS and Citigroup hold Neutral ratings with targets of $220 and $235 respectively [11] Current Performance - AbbVie’s stock price is currently at $229.06, reflecting a decrease of 1.65% with a trading volume of 1,945,474 [13] - The next earnings report for AbbVie is scheduled in 71 days, and current RSI values indicate a neutral position [13]

Core Insights - AbbVie reported third-quarter 2025 results, beating estimates for both earnings and sales, with sales increasing by 9.1% year over year, while earnings declined by 38% due to acquisition-related costs [1][9] - The company raised its revenue and EPS guidance for 2025 for the third time this year, supported by strong year-to-date momentum [1] Sales Performance - AbbVie's stock initially declined post-earnings release due to softer sales in oncology drugs and ongoing weakness in the Aesthetics unit, but later recovered and crossed the 50-day moving average [2] - Sales of AbbVie's ex-Humira drugs rose over 20% in Q3, driven by strong performances from Skyrizi and Rinvoq, which generated combined sales of $18.5 billion in the first nine months of 2025 [24][4] Drug Portfolio - AbbVie successfully navigated the loss of exclusivity for Humira by launching new immunology drugs, Skyrizi and Rinvoq, which are expected to support top-line growth in the coming years [3][5] - Skyrizi is annualizing at almost $18 billion, while Rinvoq is at over $8 billion, with expectations to exceed combined sales of $25 billion in 2025 and $31 billion by 2027 [5] Oncology and Neuroscience Contributions - The oncology segment generated combined revenues of $5.0 billion in the first nine months of 2025, up 2.7% year over year, driven by higher sales of Venclexta and contributions from new drugs [7] - AbbVie's neuroscience portfolio saw a 20.3% increase in sales to nearly $7.8 billion, supported by higher sales of Botox Therapeutic and newer migraine drugs [8] Challenges and Adjustments - AbbVie is experiencing declining sales in its Aesthetics unit, with global sales down 0.6% in 2024 and 7.4% in the first nine months of 2025, attributed to macroeconomic challenges and low consumer sentiment [13][14] - The company lowered its expectations for the Aesthetics business from $5.1 billion to $4.9 billion due to greater-than-expected market softness [15] Financial Outlook - AbbVie stock has risen 31.6% year-to-date, outperforming the industry and S&P 500 [16] - The stock is reasonably priced with a forward P/E ratio of 16.74, lower than the industry average of 16.81 [19] - Despite recent estimate declines, AbbVie expects to return to mid-single-digit revenue growth in 2025, driven by robust performances from Skyrizi and Rinvoq [25][26]

Core Insights - Investors are showing a bullish sentiment towards AbbVie (NYSE:ABBV), with significant options trading activity indicating potential upcoming developments [1][2] - The overall sentiment among large traders is 69% bullish and 30% bearish, with a total of $1.16 million in options trades identified [2] - The targeted price range for AbbVie over the last three months is between $170.0 and $225.0, based on volume and open interest analysis [3] Options Activity - The average open interest for AbbVie options is 1,766.69, with total trading volume reaching 3,346.00 in the last 30 days [4] - Notable options trades include a mix of calls and puts, with significant amounts allocated to both bullish and bearish positions [10] Company Overview - AbbVie is a pharmaceutical company with a strong focus on immunology and oncology, having expanded its portfolio through acquisitions, including Allergan in 2020 and recent acquisitions in neuroscience and oncology [11] - Analysts have set an average target price of $259.0 for AbbVie, with varying ratings from different firms, indicating a generally positive outlook [13][14] Current Market Position - AbbVie is currently trading at $215.9, reflecting a decrease of 0.98%, with a trading volume of 2,126,342 [16]

Core Insights - AbbVie Inc. reported third-quarter 2025 sales of $15.78 billion, exceeding the consensus estimate of $15.59 billion, with a reported sales increase of 9.1% and an operational increase of 8.4% [1] - Adjusted earnings per share were $1.86, down 38% year-over-year, but above the consensus of $1.79 [1] - The company raised its quarterly dividend from $1.64 to $1.73 per share, reflecting confidence in its financial performance [1][2] Sales Performance - The immunology portfolio generated $7.89 billion in global net revenues, up 11.9% (+11.2% operationally), driven by Skyrizi sales of $4.71 billion (+46.8%) and Rinvoq sales of $2.18 billion (+35.3%); however, Humira sales fell to $993 million (-55.4%) [2] - The oncology portfolio saw sales of $1.68 billion, a slight decrease of 0.03% (-1.3%), with Imbruvica revenues at $706 million (-14.8%) and Venclexta revenues at $726 million (+7.1%) [3] - Neuroscience portfolio sales increased by 20.2% to $2.84 billion, with Vraylar revenues at $934 million (+6.7%) and Botox Therapeutics at $985 million (+16.1%) [3] Guidance and Future Outlook - AbbVie raised its fiscal 2025 adjusted earnings guidance to a range of $10.61-$10.65 per share, compared to the previous range of $10.38-$10.58, against a consensus of $10.53 [4] - The updated guidance accounts for a $2.05 per share negative impact from acquired IPR&D and milestone expenses incurred year-to-date [4] Analyst Commentary - Analysts from William Blair noted that AbbVie's immunology and inflammation franchises are exceeding expectations, contributing positively to total revenue growth [5] - There are anticipated growth drivers in the Parkinson's disease franchise and potential from the late-stage ADC portfolio [5] - AbbVie shares are currently trading at 15.8 times the 2026 consensus EPS, which does not fully reflect the company's growth profile, leading to an Outperform rating from analysts [6]